Skip to main content

Table 2 Patient characteristics

From: The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

  

NNRTI

PI

Other

Total

(n = 46) [34.6%]

(n = 38) [28.6%]

(n = 49) [36.8%]

(N = 133)

Sociodemographic factors

Patient age (in years) at diagnosis

<50

36 [78.3%]

34 [89.5%]

43 [87.8%]

113 [85.0%]

≥50

10 [21.7%]

4 [10.5%]

6 [12.2%]

20 [15.0%]

Education level (college degree)

No

36 [78.3%]

31 [81.6%]

41 [83.7%]

108 [81.2%]

Yes

10 [21.7%]

7 [18.4%]

8 [16.3%]

25 [18.8%]

Anamnestic factors

HIV stage according to CDC classification

A + B

41 [89.1%]

24 [63.2%]

36 [73.5%]

101 [75.9%]

C (AIDS)

5 [10.9%]

14 [36.8%]

13 [26.5%]

32 [24.1%]

Three or more concomitant diseases

No

37 [80.4%]

29 [76.3%]

39 [79.6%]

105 [78.9%]

Yes

9 [19.6%]

9 [23.7%]

10 [20.4%]

28 [21.1%]